Study directory

Bipolarity studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1909studies shown
Showing 1,021-1,032 of 1,909
Drug study icon
UnknownNCT03423680

Abilify® Tablet(Aripiprazole) for depression in bipolarity

This study has an unknown status in South Korea. It is testing abilify® Tablet(Aripiprazole) for depression in bipolarity.

In Seoul
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, DepressionDrugA study involving a medication or substance.From 19 Years to 70 Years
Countries
South Korea
Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT00094432

Aripiprazole in people with Bipolarity type I With a Major Depressive Episode

This study is completed in the United States. It is testing aripiprazole for depression.

Multiple locations, including Mesa
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT05328297

JNJ-55308942 for depression in bipolarity

This study is completed in the United States, in Canada, in Poland, .... It is testing JNJ-55308942 for depression in bipolarity.

Multiple locations, including Huntsville
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, DepressionDrugFrom 18 Years to 64 Years
Countries
United States, Canada, Poland, ...
Sponsor
Janssen Pharmaceutica N.V., Belgium
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT00892125

Safety study of Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in schizophrenia

This study is completed. It is testing Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) for schizophrenia.

Location not clearly listed
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, SchizophreniaDrugFrom 18 Years to 55 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Bipolarity, Schizophrenia
Drug study icon
CompletedNCT01725308

Efficacy of FK949E in Bipolarity people with Major Depressive Episodes

This study is completed in Japan. It is testing Efficacy of FK949E for depression.

Multiple locations, including Aichi
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, DepressionDrugFrom 20 Years to 64 Years
Countries
Japan
Sponsor
Astellas Pharma Inc
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT01206517

Safety study of sublingual Asenapine in schizophrenia

This study is completed. It is testing sublingual Asenapine for schizophrenia.

Location not clearly listed
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, SchizophreniaDrugFrom 10 Years to 17 Years
Countries
Sponsor
Organon and Co
Condition
Bipolarity, Schizophrenia
Drug study icon
CompletedNCT06024239

Safety study of Pharmacokinetics, Safety, and Tolerability of ABBV-932 in anxiety

This study is completed in the United States. It is testing Pharmacokinetics, Safety, and Tolerability of ABBV-932 for anxiety.

Multiple locations, including Los Alamitos
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, AnxietyDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
AbbVie
Condition
Bipolarity, Anxiety
Drug study icon
CompletedNCT00035802

Effectiveness of topiramate Compared to Placebo in Bipolarity

This study is completed. It is testing topiramate Compared to Placebo for Bipolarity.

Location not clearly listed
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, SchizophreniaDrugFrom 13 Years to 17 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Bipolarity, Schizophrenia
Drug study icon
CompletedNCT04030143

A study of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolarity type I

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, SchizophreniaDrugFrom 18 Years to 64 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity, Schizophrenia
Drug study icon
CompletedNCT03854409

A study of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolarity type I

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, SchizophreniaDrugFrom 18 Years to 64 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity, Schizophrenia
Other study type icon
CompletedNCT00071669

Acupuncture as a Supplemental Treatment for Depression in bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In Dallas
Why is this study shown?

This study includes Bipolarity among several conditions.

Bipolarity, DepressionOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Texas Southwestern Medical Center
Condition
Bipolarity, Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.